Genprex, Inc. — Director's Dealing 2026

Feb 27, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Genprex, Inc. (GNPX)
CIK: 0001595248
Period of Report: 2026-02-27

Reporting Person: Berger Mark Stanley (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-27	Common Stock	F	7168	$2	Disposed	21692	Direct

Footnotes

F1: Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).